T-cell leukemia

Summary

T-cell leukemia (MONDO:0005525) is a cancer and 13 clinical trials. Top therapeutic interventions include daclizumab, mogamulizumab, and prednisolone. A subtype of leukocyte disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 13

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	T-cell leukemia
Mondo ID	MONDO:0005525
EFO	EFO:0005592
MeSH	D015458
DOID	DOID:715
UMLS	C0023492
MedGen	6064
GARD	0024203
Is cancer (heuristic)	yes

Also known as: leukaemia (disease) of T cell · leukemia (disease) of T cell · T cell leukaemia (disease) · T cell leukemia (disease)

Disease family

This is a subtype of leukocyte disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › T-cell leukemia

Related subtypes (22): human monocytic ehrlichiosis, B cell deficiency, leukopenia, B-cell neoplasm, dendritic cell sarcoma, human granulocytic anaplasmosis, phagocyte bactericidal dysfunction, EBV-positive T-cell lymphoproliferative disorder of childhood, small intestinal enteropathy-associated T-cell lymphoma, pituitary gland basophil adenoma, leukostasis, mastocytosis, hereditary neutrophilia, Pelger-Huet anomaly, functional neutrophil defect, thymoma type B, POEMS syndrome, Langerhans cell histiocytosis, subcutaneous panniculitis-like T-cell lymphoma, eosinophil peroxidase deficiency, eosinophil disorder, mast cell activation syndrome

Subtypes (3): T-cell adult acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, adult T-cell leukemia/lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetaminophen, Dexamethasone, Diphenhydramine, Isatuximab, Ranitidine, Tucidinostat.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	5
PHASE2	3
PHASE1/PHASE2	2
Not specified	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06420076	PHASE1/PHASE2	RECRUITING	Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
NCT06698003	PHASE2	RECRUITING	A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
NCT00001941	PHASE1/PHASE2	COMPLETED	Anti-Tac for Treatment of Leukemia
NCT00611208	PHASE2	COMPLETED	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
NCT04689659	PHASE2	COMPLETED	Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
NCT03829540	PHASE1	RECRUITING	CD4CAR for CD4+ Leukemia and Lymphoma
NCT03792256	PHASE1	COMPLETED	Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
NCT04840875	PHASE1	COMPLETED	Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma
NCT04973527	PHASE1	TERMINATED	LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
NCT05513612	PHASE1	WITHDRAWN	Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
NCT04264078	EARLY_PHASE1	UNKNOWN	Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
NCT04411043	Not specified	RECRUITING	Observatory of Prolymphocytic Leukemia T
NCT06600568	Not specified	RECRUITING	Novel Therapeutic Approach for Human T-cell Malignancies

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACLIZUMAB	4	1
MOGAMULIZUMAB	4	1
PREDNISOLONE	4	1
RESIMMUNE	2	1